Mr. Erik L. Kreider
CEO
Kabana Skin Care LLC
685 S Arthur Ave Unit 9b
Louisville , CO 80027-3141
United StatesFEI 3015118914Issued Jul 18, 2025Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3015118914.
Violations3
Issue DateJul 18, 2025
Product TypeDrugs
StatusOpen
Letter Details
Firm
Kabana Skin Care LLC
Location
Mr. Erik L. Kreider
CEO
Kabana Skin Care LLC
685 S Arthur Ave Unit 9b
Louisville , CO 80027-3141
United States
FEI Number
3015118914
Country
United States
Issue Date
July 18, 2025
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Summary
Kabana Skin Care LLC, a manufacturer of over-the-counter drugs including sunscreens and antibacterial hand sanitizers, was cited for significant Current Good Manufacturing Practice (CGMP) violations that rendered their finished drug products adulterated. During a February 2025 inspection, the FDA found the company failed to adequately test incoming components such as ethanol and glycerin for identity and conformity with written specifications, and failed to validate and establish the reliability of their component suppliers' test analyses at appropriate intervals as required by 21 CFR 211.84(d). The company's March 2025 response to the FDA's inspection findings was deemed inadequate due to lack of supportive documentation and insufficient evidence of corrective actions to achieve CGMP compliance.
Kabana Skin Care LLC FDA Warning Letter, July 18, 2025